2-[2-(5-溴-1H-吲哚-3-基)乙基]-3-[3-(1-甲基乙氧基)苯基]-4-(3H-)-喹唑啉酮 | 133040-77-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 2-[2-(5-溴-1H-吲哚-3-基)乙基]-3-[3-(1-甲基乙氧基)苯基]-4-(3H-)-喹唑啉酮
• 英文名称: LY 202769
• 英文别名: 2-[2-(5-Bromo-1H-indol-3-YL)ethyl]-3-[3-(1-methylethoxy)phenyl]-4-(3H)-quinazolinone；2-[2-(5-bromo-1H-indol-3-yl)ethyl]-3-(3-propan-2-yloxyphenyl)quinazolin-4-one
• CAS: 133040-77-4
• 化学式: C₂₇H₂₄BrN₃O₂
• mdl: MFCD00907856
• 分子量: 502.41
• InChiKey: KUECXUACQOYKNB-UHFFFAOYSA-N

物化性质

• 闪点：
  337 - 405℃
• 溶解度：
  二甲基亚砜：>20mg/mL

计算性质

• 辛醇/水分配系数(LogP)：
  5.9
• 重原子数：
  33
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.185
• 拓扑面积：
  57.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-氨基苯异丙醚 在 4-甲基苯磺酸吡啶 作用下， 以 吡啶 为溶剂， 反应 86.0h， 生成 2-[2-(5-溴-1H-吲哚-3-基)乙基]-3-[3-(1-甲基乙氧基)苯基]-4-(3H-)-喹唑啉酮
  参考文献：
  名称：

  喹唑啉酮胆囊收缩素-B受体配体。

  摘要：

  DOI：

  10.1021/jm00108a040

文献信息

• 3-aryl-4(3H) quinazolinone CCK antagonists and pharmaceutical
  申请人：Eli Lilly and Company

  公开号：US05196427A1

  公开（公告）日：1993-03-23

  Novel substituted quinazolinones have been found to exhibit specific binding to cholecystokinin (CCK) receptors in the brain and/or peripheral site such as the pancreas and ileum. The quinazolinones are CCK receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders and central nervous system disorders, and are useful for appetite regulation in mammals. Pharmaceutical formulations for such indications are described.

  已发现新型取代喹唑啉酮具有与胆囊收缩素（CCK）受体在大脑和/或外周部位（例如胰腺和回肠）特异性结合的作用。这些喹唑啉酮是CCK受体拮抗剂，可用于治疗胃肠道和中枢神经系统疾病，并可用于哺乳动物的食欲调节。本文描述了用于这些适应症的制药配方。
• 3-aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical
  申请人：Eli Lilly and Company

  公开号：US05075313A1

  公开（公告）日：1991-12-24

  Novel substituted quinazolinones have been found to exhibit specific binding to cholecystokinin (CCK) receptors in the brain and/or peripheral site such as the pancreas and ileum. The quinazolinones are CCK receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders and central nervous system disorders, and are useful for appetite regulation in mammals. Pharmaceutical formulations for such indications are described.

  发现新型取代喹唑啉类化合物可以在大脑和/或外周部位如胰腺和回肠中特异性结合胆囊收缩素（CCK）受体。这些喹唑啉类化合物是CCK受体拮抗剂，适用于治疗胃肠道疾病和中枢神经系统疾病，并且对哺乳动物的食欲调节有用。描述了用于这些适应症的制药配方。
• 3-Aryl-4(3H)quinazolinone CCK antagonists and pharmaceutical formulations thereof
  申请人：ELI LILLY AND COMPANY

  公开号：EP0475755A1

  公开（公告）日：1992-03-18

  Novel substituted quinazolinones have been found to exhibit specific binding to cholecystokinin (CCK) receptors in the brain and/or peripheral site such as the pancreas and ileum. The quinazolinones are CCK receptor antagonists and find therapeutic application in the treatment of gastrointestinal disorders and central nervous system disorders, and are useful for appetite regulation in mammals. Pharmaceutical formulations for such indications are described.

  研究发现，新型取代喹唑啉酮与大脑和/或胰腺和回肠等外周部位的胆囊收缩素（CCK）受体有特异性结合。喹唑啉酮类化合物是 CCK 受体拮抗剂，可用于治疗胃肠道疾病和中枢神经系统疾病，并可调节哺乳动物的食欲。本文介绍了用于此类适应症的药物制剂。
• Central cholecystokinin antagonists having pharmaceutical activity
  申请人：MERCK SHARP & DOHME LTD.

  公开号：EP0729752A2

  公开（公告）日：1996-09-04

  Pharmaceutical compositions and methods of using CCK-ligands as antipsychotic, antianxiety, and agents useful in treatment or prevention of withdrawal symptoms caused by withdrawal of chronic or long-term use of diazepam, alcohol, cocaine, or nicotine, and antianxiety agents are described.

  描述了使用 CCK 配体作为抗精神病药、抗焦虑药和治疗或预防因长期或长期使用地西泮、酒精、可卡因或尼古丁以及抗焦虑药而引起的戒断症状的药物组合物和方法。
• YU, MELVIN J.;THRASHER, K. JEFF;MC. , COWAN JEFFERSON R.;MASON, NORMAN R.+, J. MED. CHEM., 34,(1991) N, C. 1505-1508
  作者：YU, MELVIN J.、THRASHER, K. JEFF、MC. , COWAN JEFFERSON R.、MASON, NORMAN R.+

  DOI：——

  日期：——